The ShcA SH2 domain engages a 14-3-3/PI3′K signaling complex and promotes breast cancer cell survival

[1]  Dihua Yu,et al.  Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit , 2011, Oncogene.

[2]  C. Arteaga,et al.  ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. , 2011, Cancer research.

[3]  Huamin Wang,et al.  14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability. , 2011, Cancer research.

[4]  T. Pawson,et al.  Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. , 2010, Cancer research.

[5]  W. Muller,et al.  A novel role for 14-3-3sigma in regulating epithelial cell polarity. , 2010, Genes & development.

[6]  M. Hung,et al.  14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. , 2009, Cancer cell.

[7]  D. Levy,et al.  Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. , 2009, Cancer research.

[8]  J. Petrik,et al.  Reversibility and recurrence of IGF-IR-induced mammary tumors , 2009, Oncogene.

[9]  K. Brown,et al.  Unraveling Breast Cancer Heterogeneity Through Transcriptomic and Epigenomic Analysis , 2009, Annals of Surgical Oncology.

[10]  Peter Hoffmann,et al.  14-3-3:Shc Scaffolds Integrate Phosphoserine and Phosphotyrosine Signaling to Regulate Phosphatidylinositol 3-Kinase Activation and Cell Survival* , 2009, Journal of Biological Chemistry.

[11]  S. Dalal,et al.  A novel pocket in 14-3-3epsilon is required to mediate specific complex formation with cdc25C and to inhibit cell cycle progression upon activation of checkpoint pathways. , 2009, Experimental cell research.

[12]  Hua Guo,et al.  14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. , 2009, Cancer research.

[13]  F. Tashiro,et al.  A Novel Binding Factor of 14-3-3β Functions as a Transcriptional Repressor and Promotes Anchorage-independent Growth, Tumorigenicity, and Metastasis* , 2008, Journal of Biological Chemistry.

[14]  J. Ladbury,et al.  A phosphorylation-dependent gating mechanism controls the SH2 domain interactions of the Shc adaptor protein. , 2008, Journal of molecular biology.

[15]  T. Pawson,et al.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer , 2008, The EMBO journal.

[16]  D. Huntsman,et al.  Elevated Expression of DecR1 Impairs ErbB2/Neu-Induced Mammary Tumor Development , 2007, Molecular and Cellular Biology.

[17]  J. Fawcett,et al.  Combinatorial ShcA Docking Interactions Support Diversity in Tissue Morphogenesis , 2007, Science.

[18]  D. Sgroi,et al.  p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy , 2006, Breast Cancer Research.

[19]  J. Gray,et al.  Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. , 2005, Cancer research.

[20]  P. Pelicci,et al.  Cooperation and selectivity of the two Grb2 binding sites of p52Shc in T-cell antigen receptor signaling to Ras family GTPases and Myc-dependent survival , 2005, Oncogene.

[21]  Kang Z. Liu,et al.  A Role for 14-3-3τ in E2F1 Stabilization and DNA Damage-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[22]  Rakesh Kumar,et al.  The role of adapter protein Shc in estrogen non-genomic action , 2004, Steroids.

[23]  R. Cardiff,et al.  Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression , 2003, Oncogene.

[24]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[25]  R. Bagdasaryan,et al.  Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. , 2003, Cancer research.

[26]  M. Moran,et al.  Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer , 2001, Molecular and Cellular Biology.

[27]  B. Neel,et al.  New Role for Shc in Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway , 2000, Molecular and Cellular Biology.

[28]  M. Welham,et al.  Shc associates with the IL-3 receptor β subunit, SHIP and Gab2 following IL-3 stimulation , 2000 .

[29]  T. Pawson,et al.  Accelerated Mammary Tumor Development in Mutant Polyomavirus Middle T Transgenic Mice Expressing Elevated Levels of Either the Shc or Grb2 Adapter Protein , 1999, Molecular and Cellular Biology.

[30]  J. Koland,et al.  Mutation of a Shc Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-dependent Activation of Mitogen-activated Protein Kinase* , 1998, The Journal of Biological Chemistry.

[31]  John N. Hutchinson,et al.  Requirement for Both Shc and Phosphatidylinositol 3′ Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis , 1998, Molecular and Cellular Biology.

[32]  M. Moran,et al.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation , 1997, Molecular and cellular biology.

[33]  S. Fesik,et al.  Binding Affinities of Tyrosine-phosphorylated Peptides to the COOH-terminal SH2 and NH-terminal Phosphotyrosine Binding Domains of Shc (*) , 1996, The Journal of Biological Chemistry.

[34]  Tony Pawson,et al.  The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein–protein interactions , 1996, Current Biology.

[35]  M. Shibuya,et al.  A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL‐3. , 1996, The EMBO journal.

[36]  B. Margolis,et al.  The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor , 1995, Molecular and cellular biology.

[37]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[38]  T. Roberts,et al.  Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Sheila M. Thomas,et al.  Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases , 1992, Nature.

[40]  B. Margolis,et al.  Phosphatidylinositol 3′‐kinase is activated by association with IRS‐1 during insulin stimulation. , 1992, The EMBO journal.

[41]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[42]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[43]  B E Griffin,et al.  Monoclonal antibodies against polyoma virus tumor antigens. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Morrison,et al.  The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. , 2009, Trends in cell biology.

[45]  M. Welham,et al.  Shc associates with the IL-3 receptor beta subunit, SHIP and Gab2 following IL-3 stimulation. Contribution of Shc PTB and SH2 domains. , 2000, Cellular signalling.

[46]  N. Asai,et al.  The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the shc phosphotyrosine-binding domain. , 1999, Endocrinology.